Myocardial infarction and atrial fibrillation: different impact of anti-IIa vs anti-Xa new oral anticoagulants: a meta-analysis of the interventional trials.
The aim of this study was to perform a meta-analysis, in patients with atrial fibrillation, to evaluate the impact of new oral anticoagulants (NOACs) anti-IIa and anti-Xa vs warfarin on myocardial infarction incidence. A meta-analysis of double blind randomized controlled trials (RCTs) was performed. Four RCT studies including 84,439 patients were selected. Compared with warfarin, no significant reduction of myocardial infarction was observed with anti-Xa drugs; conversely, myocardial infarction was significantly increased with anti-IIa NOAC (1.45% vs 1.04% respectively; RR: 1.38; 95% CI, 1.1-1.7; p=0.005). This meta-analysis suggests that in patients with atrial fibrillation, compared to standard therapy with warfarin, treatment with anti-IIa NOAC is associated with a higher incidence of myocardial infarction.